0.8154
price down icon0.56%   -0.0046
pre-market  プレマーケット:  .91   0.0946   +11.60%
loading
前日終値:
$0.82
開ける:
$0.8766
24時間の取引高:
1.18M
Relative Volume:
0.59
時価総額:
$150.41M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-0.5585
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-5.32%
1か月 パフォーマンス:
-8.57%
6か月 パフォーマンス:
-37.76%
1年 パフォーマンス:
-4.07%
1日の値動き範囲:
Value
$0.805
$0.93
1週間の範囲:
Value
$0.79
$0.93
52週間の値動き範囲:
Value
$0.65
$1.928

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1169)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
137
Name
Twitter
@nektarnews
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

NKTR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NKTR
Nektar Therapeutics
0.8154 150.41M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
07:40 AM

Oppenheimer Upgrades Nektar Therapeutics (NKTR) to Outperform - StreetInsider.com

07:40 AM
pulisher
07:24 AM

Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6 - Marketscreener.com

07:24 AM
pulisher
Mar 13, 2025

Nektar Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

BTIG keeps Nektar stock Neutral with $4.00 target By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Promising Pipeline and Strategic Positioning: Julian Harrison’s Buy Rating on Nektar Therapeutics - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up - Yahoo Finance

Mar 13, 2025
pulisher
Mar 13, 2025

Nektar Therapeutics: Poised for Growth with Promising Rezpeg Study and Market Potential - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Assessing Nektar Therapeutics: Insights From 4 Financial Analysts - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

BTIG keeps Nektar stock Neutral with $4.00 target - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Jefferies cuts Nektar stock target to $1.00, maintains hold - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Mar 13, 2025
pulisher
Mar 13, 2025

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com

Mar 13, 2025
pulisher
Mar 12, 2025

Nektar Therapeutics Reports 2024 Financial Progress - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar reports Q4 adjusted EPS (15c), consensus (19c) - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar: Q4 Earnings Snapshot - San Antonio Express-News

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

NEKTAR THERAPEUTICS Earnings Results: $NKTR Reports Quarterly Earnings - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Earnings call transcript: Nektar Therapeutics’ Q4 2024 beats EPS expectations, stock surges - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar: Q4 Earnings Snapshot -March 12, 2025 at 06:13 pm EDT - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar Therapeutics reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - Longview News-Journal

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar Therapeutics shares rise on Q4 earnings beat By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar Therapeutics shares rise on Q4 earnings beat - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Nektar Therapeutics (NKTR) Tops Q4 EPS by 19c - StreetInsider.com

Mar 12, 2025
pulisher
Mar 12, 2025

Alopecia Areata Market to Expand Significantly by 2032, States DelveInsight Report | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart

Mar 12, 2025
pulisher
Mar 08, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives $4.08 Consensus PT from Brokerages - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

AstraZeneca selects Daiichi Sankyo as US marketing partner for Movantik - FirstWord Pharma

Mar 07, 2025
pulisher
Mar 07, 2025

AstraZeneca, Nektar's Moventig recommended for approval in Europe - FirstWord Pharma

Mar 07, 2025
pulisher
Mar 07, 2025

Nektar Therapeutics to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 05, 2025

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets - Longview News-Journal

Mar 05, 2025
pulisher
Mar 05, 2025

Metastatic Melanoma Pipeline 2024: Key Companies, MOA, ROA, - openPR

Mar 05, 2025
pulisher
Mar 01, 2025

Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata - MSN

Mar 01, 2025
pulisher
Mar 01, 2025

HC Wainwright Reiterates Buy Rating for Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Nektar Therapeutics (NKTR) Expected to Announce Earnings on Monday - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives "Market Perform" Rating from William Blair - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Bambusa Therapeutics doses first volunteers in Phase I bispecific AD trial - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

Investor Network: Nektar Therapeutics to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 26, 2025

Nektar completes enrollment for alopecia study of rezpegaldesleukin By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Nektar completes enrollment for alopecia study of rezpegaldesleukin - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Nektar Therapeutics (NKTR) Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin - StreetInsider.com

Feb 26, 2025
pulisher
Feb 26, 2025

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata - Longview News-Journal

Feb 26, 2025
pulisher
Feb 25, 2025

Buy Rating for Nektar Therapeutics: Strategic Collaboration with TrialNet Enhances Rezpeg’s Potential in Type 1 Diabetes - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

H.C. Wainwright maintains $6.50 target on Nektar stock By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 25, 2025

H.C. Wainwright maintains $6.50 target on Nektar stock - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider.com

Feb 25, 2025
pulisher
Feb 25, 2025

Piper Sandler maintains $7 target on Nektar stock post-event - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Piper Sandler maintains $7 target on Nektar stock post-event By Investing.com - Investing.com South Africa

Feb 25, 2025

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nektar Therapeutics (NKTR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Wilson Mark Andrew
Chief Legal Officer
Feb 19 '25
Sale
1.01
11,040
11,150
324,292
ROBIN HOWARD W
President & CEO
Feb 19 '25
Sale
1.01
23,774
24,012
1,086,901
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
大文字化:     |  ボリューム (24 時間):